Response Predictors of Repetitive Neuromuscular Magnetic Stimulation in the Preventive Treatment of Episodic Migraine.

Background: Repetitive neuromuscular magnetic stimulation (rNMS) of the trapezius muscles showed beneficial effects in preventing episodic migraine. However, clinical characteristics that predict a favorable response to rNMS are unknown. The objective of this analysis is to identify such predictors.
Methods: Thirty participants with a diagnosis of episodic migraine (mean age: 24.8 ± 4.0 years, 29 females), who were prospectively enrolled in two non-sham-controlled studies evaluating the effects of rNMS were analyzed. In these studies, the interventional stimulation of the bilateral trapezius muscles was applied in six sessions and distributed over two consecutive weeks. Baseline and follow-up assessments included the continuous documentation of a headache calendar over 30 days before and after the stimulation period, the Migraine Disability Assessment Score (MIDAS) questionnaire (before stimulation and 90 days after stimulation), and measurements of pain pressure thresholds (PPTs) above the trapezius muscles by algometry (before and after each stimulation session). Participants were classified as responders based on a ≥25% reduction in the variable of interest (headache frequency, headache intensity, days with analgesic intake, MIDAS score, left-sided PPTs, right-sided PPTs). Post-hoc univariate and multivariate binary logistic regression analyses were performed.
Results: Lower headache frequency ( P = 0.016) and intensity at baseline ( P = 0.015) and a migraine diagnosis without a concurrent tension-type headache component ( P = 0.011) were significantly related to a ≥25% reduction in headache frequency. Higher headache frequency ( P = 0.052) and intensity at baseline ( P = 0.014) were significantly associated with a ≥25% reduction in monthly days with analgesic intake. Lower right-sided PPTs at baseline were significantly related to a ≥25% increase in right-sided PPTs ( P = 0.015) and left-sided PPTs ( P =0.030). Performance of rNMS with higher stimulation intensities was significantly associated with a ≥25% reduction in headache intensity ( P = 0.046).
Conclusions: Clinical headache characteristics at baseline, the level of muscular hyperalgesia, and stimulation intensity may inform about how well an individual patient responds to rNMS. These factors may allow an early identification of patients that would most likely benefit from rNMS.
Competing Interests: The Division of Pediatric Neurology and Developmental Medicine, Dr. von Hauner Children's Hospital, LMU Hospital, Munich Germany is provided by an emFieldPro magnetic stimulator by Zimmer MedizinSysteme GmbH (Neu-Ulm, Germany). NS and SK received honoraria from Nexstim Plc (Helsinki, Finland). SK received honoraria from Brainlab AG (Munich, Germany), Spineart (Frankfurt, Germany), Ulrich Medical (Ulm, Germany), Zeiss Meditec (Jena, Germany), and Medtronic (Dublin, Ireland). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2022 Börner, Renner, Trepte-Freisleder, Urban, Schandelmaier, Lang, Lechner, Koenig, Klose, Albers, Krieg, Baum, Heinen, Landgraf, Sollmann and Bonfert.)